TSANZ SIG Orals: COPD 2
Tracks
TSANZ Orals
| Sunday, March 23, 2025 |
| 1:00 PM - 2:30 PM |
Speaker
Prerna Mehta
Medical Science Liaision
Sanofi
Dupilumab in COPD with type 2 inflammation: Pooled BOREAS/NOTUS trials
1:00 PM - 1:15 PM
Dr Thomas Bradbury
Project Coordinator
The George Institute for Global Health
Low-dose bisoprolol does not cause acute worsening in COPD patient respiratory status: an updated PACE in COPD sub-analysis
1:15 PM - 1:30 PM
Dr Lee Fong
Australian Commission on Safety and Quality in Health Care
A national standard to improve care for chronic obstructive pulmonary disease
1:30 PM - 1:45 PM
Dr Sanjay Ramakrishnan
Senior Lecturer
Institute For Respiratory Health
Benralizumab for eosinophilic asthma and/or COPD exacerbations (ABRA trial)
1:45 PM - 2:00 PM
Dr Arwel Jones
Research Fellow
Monash University
Oral corticosteroid use in COPD: a national consumer survey
2:00 PM - 2:15 PM
Prof David Price
Director Of Observational and Pragmatic Research Institute
Observational and Pragmatic Research Institute
High-risk COPD patient management opportunities: Australia, US and UK comparisons
2:15 PM - 2:30 PM
